Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Hydroxy-N-Isopropyloxamic Acid is a small molecule belonging to the class of hydroxamic acids. It is primarily studied as an experimental compound and has not been approved for clinical use. The compound acts as a potent inhibitor of certain enzymes involved in amino acid biosynthesis—most notably ketol-acid reductoisomerase—which plays a crucial role in the biosynthesis of branched-chain amino acids in bacteria. By binding to the active site of this enzyme and forming a stable complex, it disrupts bacterial growth by inhibiting essential metabolic pathways. This mechanism makes it valuable for research into antibacterial agents and enzyme inhibition[1][2]. The compound is solid at room temperature with good water solubility and has been explored mainly within medicinal chemistry and drug development contexts[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-Hydroxy-N-Isopropyloxamic Acid.